Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus With Intralesional Cidofovir

Castelo‐Soccio, Leslie

doi:10.1001/archdermatol.2009.363

Cited by 47 publications

(31 citation statements)

References 10 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of its nephrotoxicity, cidofovir is routinely administered with probenecid and requires intravenous hydration. Cidofovir has proven to be effective in the treatment of progressive mucocutaneous infections due to ACV-and/or FOSresistant HSV in immunocompromised patients (41,124,130,143,202,204), but it is not approved for this indication. The safety and efficacy of single topical applications of 1, 3, and 5% cidofovir gels have been evaluated for the treatment of early, lesional, recurrent genital herpes (173), but they are not commercially available.…”

Section: Management Of Nucleoside Analogue-resistant Hsv Infectionsmentioning

confidence: 99%

Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management

Piret

Boivin

2011

Antimicrob Agents Chemother

473

406

View full text Add to dashboard Cite

Section: Management Of Nucleoside Analogue-resistant Hsv Infectionsmentioning

confidence: 99%

Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management

Piret

Boivin

2011

Antimicrob Agents Chemother

473

406

View full text Add to dashboard Cite

“…When this occurs, resolution typically occurs with intravenous foscarnet. Intravenous and intralesional cidofovir have also been used successfully to treat resistant strains [7, 8]. …”

Section: Discussionmentioning

confidence: 99%

Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV)

2017

View full text Add to dashboard Cite

Recurrent anogenital herpes simplex virus infections are common in patients with human immunodeficiency virus (HIV), of whom approximately 5% develop resistance to acyclovir. We present a case of a 49-year-old man with HIV who had an 8-year history of recurrent left inguinal herpes simplex virus type 2 ulcerations. He initially responded to oral acyclovir, but developed resistance to acyclovir and eventually foscarnet. The lesion progressed to a large hypertrophic mass that required surgical excision, which led to resolution without recurrences. Our case highlights the importance of surgical excision as a treatment option in refractory herpes simplex virus anogenital infections.

show abstract

“…Because of its nephrotoxicity, CDV is routinely administered with probenecid and requires IV hydration. Intravenous CDV has shown some efficacy in the treatment of progressive ACV-and/or FOS-resistant mucocutaneous HSV infections in immunocompromised (Snoeck et al 1994;LoPresti et al 1998;Kopp et al 2002;Castelo-Soccio et al 2010) but is not approved for this indication.…”

Section: Management Of Infections Caused By Drug-resistant Hsv and Vzmentioning

confidence: 99%

Antiviral Drug Resistance in Herpesviruses

Piret

Drouot

Boivin

2014

Handbook of Antimicrobial Resistance

View full text Add to dashboard Cite

The discovery of acyclovir (ACV), a nucleoside analogue, more than 30 years ago, represents a milestone in the management of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. The modest activity of ACV against human cytomegalovirus (HCMV) has prompted the development of another nucleoside analogue, ganciclovir (GCV), for the management of systemic and organ-specific HCMV diseases. Second-line agents such as the pyrophosphate analogue foscarnet (FOS) and the nucleotide analogue cidofovir (CDV) have been approved subsequently. In contrast to ACV and GCV, the latter drugs do not require an initial phosphorylation step by viral protein kinases to be converted into their active forms. Since the introduction of these antivirals, the emergence of drug-resistant mutants has been constantly reported particularly in severely immunocompromised patients such as bone marrow and solid organ transplant recipients as well as human immunodeficiency virus (HIV)-infected individuals. In this chapter, we review the characteristics of the antiviral agents currently approved for the management of HSV, VZV, and HCMV diseases, the laboratory methods for assessing drug susceptibilities, and the clinical significance of drug-resistant infections and their management.

show abstract

Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus With Intralesional Cidofovir

Cited by 47 publications

References 10 publications

Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management

Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management

Surgical excision for recurrent herpes simplex virus 2 (HSV-2) anogenital infection in a patient with human immunodeficiency virus (HIV)

Antiviral Drug Resistance in Herpesviruses

Contact Info

Product

Resources

About